vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and CarParts.com, Inc. (PRTS). Click either name above to swap in a different company.
BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($156.4M vs $120.4M, roughly 1.3× CarParts.com, Inc.). On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (7.5% vs -9.8%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs -8.6%).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Genuine Parts Company (GPC) is an American automotive and industrial parts distributor based in Atlanta, Georgia. Established by brothers Carlyle and Malcolm Fraser in 1928, the company has approximately 60,000 employees. In addition to the United States, GPC has operated in Australasia, Belgium, Canada, France, Germany, Mexico, the Netherlands, Poland, and the United Kingdom. GPC's subsidiaries include industrial parts distributor Motion as well as NAPA Auto Parts, which primarily sells part...
BCRX vs PRTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $156.4M | $120.4M |
| Net Profit | — | $-11.6M |
| Gross Margin | — | 33.2% |
| Operating Margin | 13.6% | — |
| Net Margin | — | -9.6% |
| Revenue YoY | 7.5% | -9.8% |
| Net Profit YoY | — | 25.0% |
| EPS (diluted) | $0.00 | $-0.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $120.4M | ||
| Q3 25 | $159.4M | $127.8M | ||
| Q2 25 | $163.4M | $151.9M | ||
| Q1 25 | $145.5M | $147.4M | ||
| Q4 24 | $131.5M | $133.5M | ||
| Q3 24 | $117.1M | $144.8M | ||
| Q2 24 | $109.3M | $144.3M |
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $-11.6M | ||
| Q3 25 | $12.9M | $-10.9M | ||
| Q2 25 | $5.1M | $-12.7M | ||
| Q1 25 | $32.0K | $-15.3M | ||
| Q4 24 | $-26.8M | $-15.4M | ||
| Q3 24 | $-14.0M | $-10.0M | ||
| Q2 24 | $-12.7M | $-8.7M |
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 33.2% | ||
| Q3 25 | 98.6% | 33.1% | ||
| Q2 25 | 98.3% | 32.8% | ||
| Q1 25 | 96.9% | 32.1% | ||
| Q4 24 | 95.4% | 32.5% | ||
| Q3 24 | 97.3% | 35.2% | ||
| Q2 24 | 98.4% | 33.5% |
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | — | ||
| Q3 25 | 18.6% | -7.9% | ||
| Q2 25 | 18.2% | -8.2% | ||
| Q1 25 | 14.6% | -10.3% | ||
| Q4 24 | -3.4% | -11.6% | ||
| Q3 24 | 6.6% | -6.9% | ||
| Q2 24 | 8.0% | -6.0% |
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | -9.6% | ||
| Q3 25 | 8.1% | -8.5% | ||
| Q2 25 | 3.1% | -8.4% | ||
| Q1 25 | 0.0% | -10.4% | ||
| Q4 24 | -20.4% | -11.5% | ||
| Q3 24 | -12.0% | -6.9% | ||
| Q2 24 | -11.6% | -6.0% |
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $-0.82 | ||
| Q3 25 | $0.06 | $-0.19 | ||
| Q2 25 | $0.02 | $-0.23 | ||
| Q1 25 | $0.00 | $-0.27 | ||
| Q4 24 | $-0.13 | $-0.28 | ||
| Q3 24 | $-0.07 | $-0.17 | ||
| Q2 24 | $-0.06 | $-0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $25.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $53.5M |
| Total Assets | $465.1M | $184.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $25.8M | ||
| Q3 25 | $212.9M | — | ||
| Q2 25 | $260.0M | — | ||
| Q1 25 | $295.1M | — | ||
| Q4 24 | $320.9M | — | ||
| Q3 24 | $96.8M | — | ||
| Q2 24 | $78.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $53.5M | ||
| Q3 25 | $-387.9M | $64.2M | ||
| Q2 25 | $-421.6M | $62.4M | ||
| Q1 25 | $-451.9M | $72.8M | ||
| Q4 24 | $-475.9M | $85.2M | ||
| Q3 24 | $-468.6M | $97.2M | ||
| Q2 24 | $-475.6M | $103.9M |
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $184.9M | ||
| Q3 25 | $446.4M | $200.3M | ||
| Q2 25 | $457.2M | $189.6M | ||
| Q1 25 | $480.0M | $216.5M | ||
| Q4 24 | $490.4M | $210.6M | ||
| Q3 24 | $491.3M | $227.6M | ||
| Q2 24 | $472.4M | $238.0M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
PRTS
Segment breakdown not available.
